SCHEMBL25920282

SCHEMBL25920282

COC/C=C/c1cncnc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.32
CHRNB2 P17787 4/20 0.32
CHRNA4 P43681 4/20 0.32
CHRNB4 P30926 2/20 0.32
CHRNA3 P32297 2/20 0.32
CHRNA7 P36544 2/20 0.32
MEN1 O00255 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
ALOX15 P16050 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32
IDO1 P14902 2/20 0.31
PADI4 Q9UM07 2/20 0.31
AKT1 P31749 1/20 0.31
KDM5B Q9UGL1 1/20 0.30
ROCK2 O75116 1/20 0.30
MAP4K4 O95819 1/20 0.30
PRKACA P17612 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25584995 0.80 CHRNB2 (0.36) NFE2L2CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL25584233 0.79 CHRNB2 (0.40) NFE2L2CHRNB2CHRNA4CYP2C9CYP2C19
SCHEMBL27660434 0.76 CHRNB2 (0.34) NFE2L2CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL25585872 0.73 CHRNB2 (0.31) CHRNB2CHRNA4
SCHEMBL10423128 0.71 AOC1 (0.45) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL13167168 0.70 CYP17A1 (0.32)
SCHEMBL7592958 0.70 IDO1 (0.63) NFE2L2MEN1KMT2AIDO1AKT1
SCHEMBL792985 0.70 IDO1 (0.63) NFE2L2MEN1KMT2AIDO1AKT1
SCHEMBL58240 0.70 IDO1 (0.63) NFE2L2MEN1KMT2AIDO1AKT1
SCHEMBL5328723 0.68 CHRNB2 (0.36) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242565-A1 Macrolides with Modified Desosamine Sugars and Uses Thereof ZIKANI THERAPEUTICS, INC. 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242565-A1 Macrolides with Modified Desosamine Sugars and Uses Thereof FUT6, DDOST, MGAM NFE2L2 4607/4885IRAK4 926/4885CHRNB2 4496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.